Privately-held Breath Therapeutics said today that it kicked off a Phase III clinical program for its liposomal formulation of cyclosporine A for the treatment of bronchiolitis obliterans syndrome.
The company’s primary drug candidate, L-CsA-i, is an inhaled therapy delivered via Pari Pharma‘s investigational eFlow nebulizer.
Get the full story at our sister site, Drug Delivery Business News.
The post Breath Therapeutics launches Ph3 trial for inhaled liposomal cyclosporine A therapy appeared first on MassDevice.
from MassDevice https://ift.tt/2UXpejU
Cap comentari:
Publica un comentari a l'entrada